New Packaging Launched for Active, Latent TB Medication

Officials with Sanofi announced the launch of new 24- and 32-count packs of rifapentine (Priftin). The 32-count package is tailored to treat those with active tuberculosis (TB) while the 24-count pack is intended for those with latent tuberculosis infection (LTBI) who are at high risk of progression to TB disease.

The new packaging features an extended shelf life of up to three years with individually perforated tablet blisters. Rifapentine for LTBI is indicated for those ≥2 years of age, while the medication for active TB is indicated for patients ≥12 years of age.

Priftin, an antimycobacterial, was first approved in 1998 for use in combination with antituberculosis medications for the treatment of active pulmonary TB caused by Mycobacterium tuberculosis. Then in 2014, Sanofi gained approval for Priftin in combination with isoniazide (INH) to treat cases of LTBI caused by Mycobacterium tuberculosis in patients at high risk of progression to TB disease.

Priftin is available as 150 mg capsules in both the new 24- and 32-count packs.